When Maria Gonzales, a 58-year-old teacher from San Antonio, was diagnosed with type 2 diabetes over a decade ago, her treatment routine grew more complex each year—first metformin, then insulin glargine, and eventually a daily ritual of injections and monitoring. But now, two landmark studies unveiled at the American Diabetes Association’s annual meeting in New Orleans offer new hope: an oral pill that could simplify care and dramatically improve blood sugar control. Known as orforglipron, this once-daily, non-injectable GLP-1 agonist has shown remarkable results in two phase 3 clinical trials involving more than 1,300 patients across 145 sites in the U.S., Europe, and Asia.
For millions living with type 2 diabetes, especially those already on insulin or metformin, managing HbA1c levels is a constant challenge. Poor control leads to complications like nerve damage, vision loss, and cardiovascular disease. Current GLP-1 therapies, while effective, require weekly injections—a barrier for many. Orforglipron, developed by Eli Lilly, could change that by offering a powerful oral alternative. In the ACHIEVE-2 trial led by Dr. Michelle Welch of Consano Clinical Research, patients on metformin who added orforglipron saw HbA1c reductions of up to 1.56% over 40 weeks—significantly outperforming dapagliflozin, a commonly prescribed SGLT2 inhibitor. Even more striking, in the ACHIEVE-5 trial led by Dr. Francesco Giorgino of the University of Bari Aldo Moro, patients already using insulin glargine experienced HbA1c drops as high as 1.88% with the 12-mg dose of orforglipron, compared to just 0.79% with placebo.
These numbers aren’t just statistically significant—they represent real-world impact. A drop of 1.5% or more in HbA1c can reduce the risk of diabetes-related complications by up to 25%, according to the American Diabetes Association. And unlike injectable GLP-1s, orforglipron is taken as a simple pill, which could vastly improve adherence. "ACHIEVE-5 results are encouraging because they suggest a once-daily oral GLP-1 option like orforglipron could help improve blood glucose control for people with type 2 diabetes who are already managing complex treatment routines, including basal insulin," said Dr. Giorgino. While the studies were funded by Eli Lilly and some authors have financial ties to biopharmaceutical companies, the data published in The Lancet and JAMA underwent rigorous peer review, lending strong credibility to the findings.
As regulatory reviews begin, health systems and patients alike are watching closely. If approved, orforglipron could become the first widely available oral GLP-1 agonist in the U.S., marking a turning point in diabetes care. For people like Maria, who once thought daily injections were her only path to control, the future may soon come in a small, swallowable tablet.